Esperion Therapeutics Inc ESPR:NASDAQ

Last Price$51.29NASDAQ Closing Price as of 4:00PM ET 1/27/20

Today's Change+2.19(4.46%)
Bid (Size)$45.00 (1)
Ask (Size)$53.00 (3)
Day Low / High$47.95 - 52.29
Volume807.5 K
 

View Biotechnology IndustryPeer Comparison as of 01/27/2020

 

Esperion Therapeutics Inc ( NASDAQ )

Price: $51.29
Change: +2.19 (4.46%)
Volume: 807.5 K
4:00PM ET 1/27/2020
 
 

Veracyte Inc ( NASDAQ )

Price: $27.01
Change: -0.48 (1.75%)
Volume: 592.7 K
4:00PM ET 1/27/2020
 
 

TG Therapeutics Inc ( NASDAQ )

Price: $13.16
Change: -0.34 (2.52%)
Volume: 1.5 M
4:00PM ET 1/27/2020
 
 

Dicerna Pharmaceuticals Inc ( NASDAQ )

Price: $18.94
Change: -0.32 (1.66%)
Volume: 339.3 K
4:00PM ET 1/27/2020
 
 

Coherus BioSciences Inc ( NASDAQ )

Price: $18.73
Change: +0.58 (3.20%)
Volume: 914.0 K
4:00PM ET 1/27/2020
 

Read more news Recent News

Insider Trends: Insider Purchase Continues Esperion Therapeutics Positive Trend
12:53PM ET 1/27/2020 MT Newswires

Target Biotech Nv, 10% Owner, purchased 20,000 shares in Esperion Therapeutics (ESPR) for $1,042,398 on Jan 23, 2020. Following the Form 4 filing with the...

Esperion Therapeutics' Pooled Analyses of Bempedoic Acid Shows Lower LDL-C, HbA1c in Diabetes Patients
8:52AM ET 11/18/2019 MT Newswires

Esperion Therapeutics (ESPR) said Monday that pooled analyses from four phase 2 clinical studies of bempedoic acid shows its drug candidate reduced...

Insiders at Esperion Therapeutics (ESPR) Make Significant purchases Extending the 90 day Trend
10:18PM ET 11/11/2019 MT Newswires

There were significant insider purchases of Esperion Therapeutics shares today, as reflected in filings with the SEC as two insiders -- Timothy M Mayleben,...

Insider Trends: Insider Buying Added to with Purchase of Esperion Therapeutics Shares
4:21PM ET 11/08/2019 MT Newswires

Timothy M Mayleben, Director and President & CEO, bought 5,000 shares in Esperion Therapeutics (ESPR) on Nov 06, 2019, for $184,900. Mayleben, after the...

View all Commentary and Analysis

Biotech Bonanza: 2020 Outlook In An Election Year
4:15PM ET 1/08/2020 Seeking Alpha

Retailers, Dubai Airshow And Cybertrucks (Stocks To Watch Podcast)
7:30AM ET 11/17/2019 Seeking Alpha

Stocks To Watch: Retailers, Dubai Airshow And Cybertrucks
7:10AM ET 11/16/2019 Seeking Alpha

Daily Insider Ratings Round Up 11/8/19
4:33PM ET 11/11/2019 Seeking Alpha

Company Profile

Business DescriptionEsperion Therapeutics, Inc. operates as a clinical stage pharmaceutical company, which engages in the development and commercialization of oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). It offers Bempedoic acid and Ezetime combination pill as therapies that have been shown to lower elevated LDL-C levels in patients with hypercholesterolemia, including patients inadequately treated with current lipid-modifying therapies. The company was founded by Roger S. Newton, Hans Ageland, Jan O. Johansson, Anders Paul Wiklund, Michael E. Pape, David I. Scheer and Charles L. Bisgaier in May 1998 and is headquartered in Ann Arbor, MI. View company web site for more details
Address3891 Ranchero Drive
Ann Arbor, Michigan 48108
Phone+1.734.887.3903
Number of Employees76
Recent SEC Filing01/27/20204
President, Chief Executive Officer & DirectorTim M. Mayleben
Chief Financial Officer & SecretaryRick Bartram
Executive Vice President-Research & DevelopmentNarendra D. Lalwani
Senior Vice President-Clinical DevelopmentWilliam J. Sasiela

Company Highlights

Price Open$48.07
Previous Close$49.10
52 Week Range$33.13 - 61.93
Market Capitalization$1.4 B
Shares Outstanding27.3 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement02/27/2020

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$3.69
Beta vs. S&P 500N/A
Revenue$0.00
Net Profit Margin-64.63%
Return on Equity-84.30%

Analyst Ratings as of 11/08/2019

Buy
9
Overweight
0
Hold
3
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset